What is Tyvaso (tyvaso ema) used for?
Tyvaso EMA refers to Tyvaso, a brand of inhaled treprostinil used for pulmonary arterial hypertension (PAH). It delivers treprostinil directly to the lungs to help improve exercise capacity and pulmonary hemodynamics in people with PAH. [1]
What does “EMA” mean for Tyvaso?
“EMA” is shorthand for the European Medicines Agency, the regulator that evaluates and authorizes medicines in the European Union. So “Tyvaso EMA” typically points to the EU (EMA) product information, regulatory status, and labeling for Tyvaso. [1]
How is Tyvaso taken?
Tyvaso is inhaled using a device designed for inhaled treprostinil administration. Dosing is individualized, and patients follow the prescribed titration and maintenance schedule in the product information. [1]
Is Tyvaso the same as other treprostinil forms?
Tyvaso specifically is inhaled treprostinil. Treprostinil also exists in other formulations (for example, other routes of administration), but the dosing, device, and clinical use can differ by formulation. [1]
What side effects do people commonly ask about?
Commonly discussed adverse effects with inhaled treprostinil include cough, headache, flushing, nausea, dizziness, and throat irritation, among others. The full list and frequencies are in the EMA-approved product information. [1]
Where to find the official EMA details?
You can check the official EMA product information (summary of product characteristics and related documents) for Tyvaso through the EMA medicines database or the product page linked to the authorized indication(s). [1]
Sources
[1] https://www.ema.europa.eu/